HC Wainwright & Co. maintains Biodesix at Buy, lowers price target to $34 from $38

HC Wainwright & Co. kept Biodesix's rating at Buy but reduced its price target to $34 from $38, a 10.5% cut. This implies a 298.6% upside from the Nov 6 close of $8.53.

Original reporting
Published Nov 9, 2026, 11:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Biodesix at Buy, lowers price target to $34 from $38 — source image
Decision brief

The 30-second read

$BDSXBearishLow
01

Why it matters

The downgrade signals a short‑term bearish bias, but the stock's low float could lead to volatility.

02

Market read

Analyst target reduction is the primary new information, offering a modest trading cue for BDSX.

03

What to watch

Potential upcoming FDA interactions or partnership announcements not covered in the brief.

Relevance 6/10Novelty 5/10Timing: today

Background

Biodesix is a diagnostic company focused on lung disease testing. Analyst coverage is limited, making target changes notable for traders.

Company-level read

Ticker impact

$BDSXBearishMedium confidence
Context

HC Wainwright lowered Biodesix's price target to $34 from $38, indicating a bearish analyst view.

Expected impact

likely pressure as the market prices in the lower target

Evidence & confidence

Target reductions often precede short‑term price declines, especially for micro‑caps.

Market effects

Minimal; reflects broader analyst caution on diagnostic biotech stocks.

Limited to US biotech sector.

Low; no global macro implications.

Counterpoint

Target cut may be overly pessimistic if upcoming trial data exceeds expectations.

Key entities

  • HC Wainwright & Co.

    Equity research firm that issued the rating and target change.

  • Biodesix Inc.

    US‑listed diagnostic biotech (ticker BDSX).

Related articles

High

Biodesix Q3FY26 Results: Revenue misses estimates, stock falls 29%

Biodesix Inc reported Q3FY26 revenue of $24.0M, missing estimates of $27.44M. Shares fell 29.44% after-hours. Full-year guidance was reduced to $101M-$103M from $108M-$114M. Revenue growth was 10% YoY, but test volume growth was offset by lower revenue per test. Gross margin remained at 81%, and net loss improved 8% YoY to $8.0M.

$BDSXMed

Biodesix Announces Third Quarter 2026 Results and Highlights

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Third Quarter 2026 Results and Highlights Delivered total revenue of $24.0 million, an increase of 10% year over year Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24% Maintained an 81% gross margin, improved Net

$BDSXMedAI 8/10

Biodesix (BDSX) Q2 2026 Earnings Call Transcript

Biodesix (BDSX) reported Q2 2026 results and discussed clinical demand drivers for its Nodify lung nodule biomarkers. The company said March publication of a lung nodule validation study increased Nodify CDT orders for nodules as small as 4 mm. Q2 revenue rose 34% to $26.9M, diagnostic testing revenue $25.4M (+42%), gross margin 82%, and net loss was $7.3M. Full-year revenue outlook remains $108M to $114M.

$BDSXHigh

Biodesix Announces Second Quarter 2026 Results and Highlights

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Confere